<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; risk</title>
	<atom:link href="http://www.tapanray.in/tag/risk/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Deadly Climate Change Impact On Human Health: How Prepared Is India?</title>
		<link>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=deadly-climate-change-impact-on-human-health-how-prepared-is-india</link>
		<comments>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/#comments</comments>
		<pubDate>Mon, 12 Aug 2019 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[Ayushman]]></category>
		<category><![CDATA[bharat]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change. global]]></category>
		<category><![CDATA[Climate]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[effect]]></category>
		<category><![CDATA[gainers]]></category>
		<category><![CDATA[greenhouse]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infectious diseases]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Paris]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researching]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tropical]]></category>
		<category><![CDATA[Trump]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[warming]]></category>
		<category><![CDATA[Zika]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9665</guid>
		<description><![CDATA[It’s not uncommon to find many people, including heads of countries, expressing their serious apprehensions in public, about the scary impact of climate change. Just the last year, on November 26, 2018, BBC News captured one of such incidences with the astonishing &#8230; <a href="http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/deadly-climate-change-impact-on-human-health-how-prepared-is-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Innovative ‘Medicines Too Damn Expensive’: Health Risk For Billions of People</title>
		<link>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people</link>
		<comments>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/#comments</comments>
		<pubDate>Mon, 18 Mar 2019 00:00:22 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ailments]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[billions]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[damn]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-saving]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[millions]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[transparency]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9448</guid>
		<description><![CDATA[Most ‘medicines are too damn expensive. And a key part of the problem is the lack of consistent information about drug pricing. It’s not often that the Trump administration and the anti-poverty NGO Oxfam find themselves singing from the same &#8230; <a href="http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/innovative-medicines-too-damn-expensive-health-risk-for-billions-of-people/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exigency of Cybersecurity in Digitalized Pharma</title>
		<link>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exigency-of-cybersecurity-in-digitalized-pharma</link>
		<comments>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/#comments</comments>
		<pubDate>Mon, 08 Oct 2018 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[attack]]></category>
		<category><![CDATA[awareness]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[cyber]]></category>
		<category><![CDATA[cybersecurity]]></category>
		<category><![CDATA[digitalized]]></category>
		<category><![CDATA[digitized]]></category>
		<category><![CDATA[employee]]></category>
		<category><![CDATA[espionage]]></category>
		<category><![CDATA[exigency]]></category>
		<category><![CDATA[experienced]]></category>
		<category><![CDATA[hack]]></category>
		<category><![CDATA[hacking]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threat]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9204</guid>
		<description><![CDATA[Digitalization – as it unfolds and imbibed by most drug companies, is presumed to herald a whole new ballgame in the Indian pharma business. Equally significant is the quantum benefit that the process will deliver to pharma stakeholders – right &#8230; <a href="http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exigency-of-cybersecurity-in-digitalized-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Relevance Of Outliers In Pharma Sales Forecasting</title>
		<link>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=relevance-of-outliers-in-pharma-sales-forecasting</link>
		<comments>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/#comments</comments>
		<pubDate>Mon, 07 Aug 2017 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[accuracy]]></category>
		<category><![CDATA[analyzing]]></category>
		<category><![CDATA[downside]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[forecast]]></category>
		<category><![CDATA[forecasting]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[launches]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[outliers]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[upside]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8341</guid>
		<description><![CDATA[Just like any other predictions or forecasting &#8211; on a broader sense, pharma sales forecasts are also a tough and tedious task. Availability of many sophisticated state of the art digital software tools and techniques, notwithstanding. In an article, published &#8230; <a href="http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/relevance-of-outliers-in-pharma-sales-forecasting/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
